European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire

Abstract

The European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a core, disease-specific assessment tool designed for use with patients undergoing treatment for cancer or those who have successfully recovered. This instrument comprehensively measures several critical aspects of a patient’s health-related quality of life (HRQoL).

The scale incorporates five functional domains, including physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. Furthermore, it assesses common symptoms associated with cancer and its treatment, such as pain, nausea and vomiting, sleep disturbance, dyspnea (shortness of breath), cancer-related fatigue, constipation, diarrhea, and financial difficulties. The instrument also includes two items dedicated to assessing overall global health status and quality of life (QoL). The generic C30 version is frequently used as a foundation that can be supplemented by tumor-specific modules, such as the EORTC QLQ-LC13 for lung cancer.

Keywords

EORTC QLQ-C30, Quality of Life, Cancer, Oncology, Patient-Reported Outcomes (PROs), Functional Status, Symptom Assessment, Health-Related Quality of Life, Psychometric Instrument.

Authors

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osaba J, Rofe PB, Roth M, Ryan L, Selby P, Simes RJ, Stuart H, van Dam F, Wierenga P. (Representing the EORTC Study Group on Quality of Life).

Purpose

The primary purpose of the EORTC QLQ-C30 is to standardize the assessment of health-related quality of life (HRQoL) in cancer patients participating in clinical trials, observational studies, and routine clinical practice. It provides a reliable and valid measure to evaluate the subjective impact of cancer and various anti-cancer treatments, such as chemotherapy, radiotherapy, and surgery, on the patient’s daily life.

Its structure allows clinicians and researchers to monitor changes in functional status and symptom burden over time. By combining generic QoL assessment with specific symptom scales relevant to oncology, the QLQ-C30 facilitates cross-cultural and cross-study comparisons of treatment efficacy, particularly when HRQoL is a critical secondary or primary endpoint in intervention studies.

Construct

The QLQ-C30 measures the multidimensional construct of Health-Related Quality of Life (HRQoL) specific to the cancer population. HRQoL, in this context, encompasses the patient’s subjective appraisal of their current health status and its impact on their physical, psychological, and social functioning. It is designed to capture the unique challenges faced by cancer patients, differentiating between general well-being and aspects directly related to the disease or its treatment.

The instrument operationalizes HRQoL through five distinct functional scales, three symptom scales, six single-item symptom measures, and one two-item global health status scale. This structure ensures that both positive aspects (functioning) and negative aspects (symptoms and side effects) of the cancer experience are captured accurately, providing a holistic view of the patient’s overall well-being and ability to cope with their condition.

Validity

The EORTC QLQ-C30 demonstrates strong evidence of construct validity. Numerous international studies have confirmed that the scale scores effectively differentiate between patient groups known to differ in health status, such as patients with different stages of disease, varying performance status, or those receiving palliative versus curative treatment. Convergent and divergent validity have been established through correlations with other standardized QoL measures, generally showing high correlation with similar domains and low correlation with unrelated domains, confirming that the scale measures the intended constructs.

Furthermore, the instrument exhibits robust cross-cultural validity. It has been meticulously translated and validated in over 100 languages following stringent EORTC methodology, ensuring its conceptual and linguistic equivalence across diverse international settings. Responsiveness, a key component of clinical validity, is high, meaning the QLQ-C30 is sensitive enough to detect clinically meaningful changes in HRQoL following therapeutic intervention or disease progression, making it suitable for longitudinal studies.

Reliability

The reliability of the EORTC QLQ-C30 is consistently high across its functional and symptom scales. Internal consistency, typically measured using Cronbach’s alpha, generally exceeds the recommended threshold of 0.70 for group comparisons, particularly for the multi-item scales like Physical Functioning and Emotional Functioning. The global health status scale also maintains acceptable internal consistency, indicating that items within each scale measure a common underlying dimension.

Test-retest reliability has been established in stable patient populations across various cancer types, confirming the stability of the scale scores over short periods when no significant clinical changes have occurred. This high level of reliability ensures that observed changes in scores are likely due to real changes in the patient’s HRQoL rather than random measurement error, thus lending confidence to the data collected in clinical trials.

Factor Analysis

Initial development and subsequent large-scale validation studies of the QLQ-C30 confirmed its hypothesized factor structure. Exploratory and confirmatory factor analysis (CFA) generally support the five functional scales (Physical, Role, Emotional, Cognitive, Social) and the three multi-item symptom scales (Fatigue, Nausea/Vomiting, Pain). This structural validation confirmed the theoretical framework underpinning the instrument.

While some minor variations in factor loadings have been observed across different cultures and specific cancer types, the core 15-scale structure remains highly stable and reproducible. The factor analysis provides strong evidence that the 30 items successfully cluster into the intended domains, supporting the standardized scoring algorithm used by the EORTC Quality of Life Group to derive the scale scores for clinical and research applications.

Instrument

Test Type: Questionnaire (Patient-Reported Outcome Measure – PROM)

Format: 30 items, administered via self-report. Most items utilize a 4-point Likert scale (“Not at all” to “Very much”). The two Global Health Status items use a 7-point scale (“Very poor” to “Excellent”). The administration typically takes 10 to 15 minutes.

Language Available: Over 100 languages validated and available through the EORTC Quality of Life Group.

Population Group: Patients diagnosed with or surviving any type of cancer.

Age Group: Adults and Elderly (Volwassenen, Ouderen).

Population Details: Applicable across all stages of disease, tumor sites, and throughout the entire treatment trajectory (curative, adjuvant, palliative, and follow-up care). The instrument is designed to be used in conjunction with disease-specific modules when necessary.

Test Methodology: Self-administered paper-and-pencil or electronic format. Raw scores are linearly transformed to a standardized 0 to 100 scale. For functional scales, higher scores indicate better functioning; for symptom scales and financial difficulties, higher scores indicate greater symptom severity or difficulty.

Keywords

Oncology Trials, Patient Functioning, Symptom Burden, HRQoL Assessment, EORTC, Psychometrics, Health Status, Cancer Survivors.

Authors

Author ORCID Identifier: ORCID identifiers are specific to individual authors within the EORTC Quality of Life Group and are not provided for the consortium as a whole.

Affiliation Email addresses: Contact managed centrally by the EORTC Quality of Life Group for permissions and distribution.

Correspondence Address: EORTC Quality of Life Group, EORTC Headquarters, Brussels, Belgium.

Permissions & Fee and Test Year

The scale was initially developed in 1988, with the widely utilized refined version published in 1993. The EORTC QLQ-C30 is generally available for academic, non-commercial research purposes free of charge, provided official registration and approval are obtained through the dedicated EORTC Quality of Life website. This registration ensures appropriate use and tracking of translations.

Commercial use, including use by pharmaceutical companies or for commercial clinical trials, typically requires a formal license agreement and payment of a licensing fee. Users must obtain the official manual and scoring guidelines from the EORTC Quality of Life Group to ensure proper application and interpretation of the standardized scoring system. The official website for registration and information is https://qol.eortc.org/.

Reference’s

The primary references for the development and validation of the core instrument are:

• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 1993; 85(5): 365-376.

• Aaronson NK, Cull A, Kaasa S, Sprangers MAG. The EORTC QLQ-C30: highly reliable, but is it valid? Journal of Clinical Oncology, 1996; 14(10): 2758-2759.

The original PDF explanation form (Toelichtingsformulier) can be downloaded here: EORTC QLQ-C30 Explanation Form.

Items of the European Organization for Research and Treatment for Cancer Quality of Life Questionnaire

IMPORTANT: The following scale items represent the domains measured by the EORTC QLQ-C30, as derived from the source content and validation structure.

The EORTC QLQ-C30 assesses 15 scales/single items, grouped into the following categories:

1. Functional Scales (5 domains, higher score = better functioning):

   • Physical Functioning

   • Role Functioning

   • Emotional Functioning

   • Cognitive Functioning

   • Social Functioning

2. Symptom Scales and Single Items (10 domains, higher score = greater severity or difficulty):

   • Fatigue (Multi-item scale)

   • Nausea and Vomiting (Multi-item scale)

   • Pain (Multi-item scale)

   • Dyspnea (Shortness of breath)

   • Insomnia (Sleep disturbance)

   • Appetite Loss

   • Constipation

   • Diarrhea

   • Financial Difficulties

   • Other general symptoms related to cancer and treatment.

3. Global Health Status / QoL Scale (2 items):

   • Overall assessment of global health status and quality of life.